Table 1: Recommended doses in patients ≥12 years of age, pharmacokinetic properties, and discontinuation intervals prior to skin prick testing* for nonsedating antihistamines.

Generic nameAcrivastineCetirizineDesloratadineEbastineFexofenadineLevocetirizineLoratadineBilastine

Dosage (mg × daily)8 × 310 × 15 × 110–20 × 1180 × 15 × 110 × 1 20 × 1
Rapid onset (h)0.5–1 0.5–1ND110.5–10.5–10.5–1
Maximum effect (h)1.5–24–6 ND4–664–64–61.3-1
Duration of effect (h)8–1224 24>24242424>24
Metabolism (%)20<10 0>900<10>900
InteractionsNoNo NoYesYesNoNoNo
Discontinuation interval (d)2333333ND

ND: no data, based on the references [8, 1416, 18, 19] and on data in product summaries of the specific drugs.